SecBot SecBot
6-K ·Filed Sep 11, 2026

GSK

GSK plc
NEUTRAL
Impact 1/10
Horizonimmediate Processed2mo ago SEC0001654954-26-008280
Notable filing: 6-K
Actionable Insight • Neutral

No material impact on GSK stock expected. Share Reward Plan acquisitions by PDMRs are routine compensation events, not discretionary insider buying. Monitor upcoming quarterly earnings for fundamental catalysts.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$48.13
T+0 close · Sep 11, 2026 · via day close
Latest settled
−3.39%
T+20 · $46.50 · next T+60 in 20d
Vs SPY
−5.26%
α at T+20
Latest observation
+6.92%
T+44 · FF3 residual α
  1. T+0 · Sep 11 $48.13entry
  2. T+1 · 2mo ago +3.99%α +4.44% · $50.05
  3. T+5 · 2mo ago +4.34%α +4.56% · $50.22
  4. T+20 · 6w ago −3.39%α −5.26% · $46.50
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

This 6-K filing reports routine acquisitions of GSK ordinary shares by multiple PDMRs (senior executives) under the company's Share Reward Plan on September 9, 2026. Each PDMR acquired 14 shares (7 partnership + 7 matching) at £18.0296 per share. The transactions are plan-based and de minimis in size, representing no material signal for the stock.

Key Facts

  • Nine PDMRs (including CFO Julie Brown, President Europe, President Corporate Development, CEO ViiV Healthcare) each acquired 14 ordinary shares under the Share Reward Plan
  • All acquisitions executed on September 9, 2026 at £18.0296 per share on the London Stock Exchange
  • Each PDMR received 7 partnership shares and 7 matching shares, standard plan structure
  • Total shares acquired across all PDMRs: 126 shares (approximately £2,272 aggregate value)
  • Transaction type is plan-based, not an open-market discretionary purchase

Financial Impact

De minimis, total consideration approximately £2,272 across all PDMRs at £18.0296/share

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-008280
Document: 0001654954-26-008280-index-headers.html0001654954-26-008280
Document: 0001654954-26-008280-index.html0001654954-26-008280
Document: 0001654954-26-008280.txt0001654954-26-008280

US Market Status

Market Closed · Opens Wed (11h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026